Last reviewed · How we verify
NCT06789757: (HCC)
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Phase 2 trial testing Memantine Hydrochloride in Hepatocellular Carcinoma in 19 participants. Currently enrolling.
27 October 2026
Quick facts
| Lead sponsor | Inova Health Care Services |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 25 February 2025 |
| Primary completion | 27 October 2026 |
| Estimated completion | 27 January 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Memantine Hydrochloride — full drug profile →
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Atezolizumab (atezolizumab) — full drug profile →
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Inova Health Care Services — full company profile →
Who can join
18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06789757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Memantine Hydrochloride
Trials testing the same drug.
- NCT06337994 — Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury · Phase 3 · completed
- NCT04966546 — Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) · EARLY_PHASE1 · withdrawn
- NCT04939597 — A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor · Phase 3 · active not recruiting
- NCT05531383 — Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury · NA · unknown
- NCT04804644 — Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippo · Phase 3 · recruiting
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Inova Health Care Services trials
Trials by the same sponsor.
- NCT06564207 — Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults · Phase 2 · not yet recruiting
- NCT07167199 — Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery · NA · not yet recruiting
- NCT07437339 — Volume Reduction for Open Fracture Irrigation · Phase 4 · recruiting
- NCT07485322 — Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center · NA · not yet recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06789757 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inova Health Care Services
- Last refreshed: 7 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing